Mosaic ImmunoEngineering (CPMV) Accumulated Depreciation (2012 - 2013)
Mosaic ImmunoEngineering (CPMV) posted quarterly Accumulated Depreciation of $44839.0 for Q2 2013, little changed year-over-year from $44667.0 in Q2 2012, and little changed quarter-over-quarter from $44667.0 in Q2 2012.
Mosaic ImmunoEngineering (CPMV) Accumulated Depreciation (2012 - 2013) Analysis & Trends
Mosaic ImmunoEngineering's Accumulated Depreciation history runs 2 years deep, the most recent figure standing at $44839.0 for Q2 2013.
- In Q2 2013, Accumulated Depreciation changed 0.39% year-over-year to $44839.0; the TTM figure through May 2013 stood at $44839.0 (changed 0.39% YoY), while the FY2013 annual figure was $44839.0, changed 0.39% from the prior year.
- Accumulated Depreciation for Q2 2013 stood at $44839.0, roughly flat from $44667.0 in the prior quarter.
- The five-year high for Accumulated Depreciation was $44839.0 in Q2 2013, with the low at $44667.0 in Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2013 | 44,839.00 |
| May 31, 2012 | 44,667.00 |